Long-term Outcomes and Prognosis for Patients with Sarcomatoid Hepatocellular Carcinoma

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2022 May 9

PMID 35530933

Authors

Cheng Zhou

Xin Zhang

Kaiqian Zhou

Yingyong Hou

Feiyu Chen

Xiangyu Zhang

Yuan Ji

Shuangjian Qiu

Jia Fan

Jian Zhou

Yuhong Zhou

Zheng Wang

Affiliations

Soon will be listed here.

Abstract

Background: Characterized by spindle cell composition in hepatocellular carcinoma tumor, sarcomatoid hepatocellular carcinoma (SHC) is a rare malignant with poor prognosis. In this study, we aimed to evaluate the clinical and pathological features of SHC and establish a nomogram that can predict long-term outcomes of the disease.

Methods: We retrospectively analyzed 63 patients who were diagnosed with SHC between October 2007 and November 2016 and used immunohistochemistry (IHC) to assessed various markers in liver samples. The clinical data and the histological and pathological findings were collected and used to build a nomogram to predict survival.

Results: The median overall survival (OS) and the recurrence-free survival (RFS) in SHC were 23.2 and 8.4 months, respectively. High expression levels of tyrosine-protein kinase Met (17/63, 27.0%) were associated with poorer RFS (P=0.040). A panel of markers, consisting heat-shock protein 70 (HSP70), glutamine synthetase (GS), and glypican-3 (GPC3), merged as an independent risk factor for treatment outcomes. The nomogram, which including this panel of markers, predicted OS times with a concordance-index (C-index) score of 0.758 (95% CI: 0.672-0.843) in the training set and 0.832 (95% CI: 0.712-0.952) in the validation set. The use of the nomogram showed marked improvements in the prediction of patient outcomes compared with conventional staging systems (P<0.05).

Conclusions: Diagnosis of SHC is rare and has a relatively poor prognosis. A panel of markers HSP70, GS and GPC3 served as an independent prognostic factor for SHC.

Citing Articles

Hepatocellular carcinoma combined with sarcomatoid hepatocellular carcinoma: A case report.

Li J, Gao X, Zhao K, Meng X, Liu S, Zhang J Medicine (Baltimore). 2024; 103(4):e37013.

PMID: 38277577 PMC: 10817123. DOI: 10.1097/MD.0000000000037013.

Surgery after combination therapy with a tyrosine kinase inhibitor and anti-PD-1 antibody in sarcomatoid hepatocellular carcinoma: case report and literature review.

Liang B, Huang T, Kuang S, Xie G, Liu T, Chen Y Front Oncol. 2023; 13:1212013.

PMID: 37869099 PMC: 10585252. DOI: 10.3389/fonc.2023.1212013.

Diagnostic accuracy and prognostic significance of Glypican-3 in hepatocellular carcinoma: A systematic review and meta-analysis.

Jiang D, Zhang Y, Wang Y, Xu F, Liang J, Wang W Front Oncol. 2022; 12:1012418.

PMID: 36212469 PMC: 9539414. DOI: 10.3389/fonc.2022.1012418.

References

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K . Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol. 1989; 23 Suppl:S4-8. DOI: 10.1007/BF00647229. View

Kang Y, Yau T, Park J, Lim H, Lee T, Obi S . Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol. 2015; 26(12):2457-63. DOI: 10.1093/annonc/mdv388. View

Lao X, Chen D, Zhang Y, Xiang J, Guo R, Lin X . Primary carcinosarcoma of the liver: clinicopathologic features of 5 cases and a review of the literature. Am J Surg Pathol. 2007; 31(6):817-26. DOI: 10.1097/01.pas.0000213431.07116.e0. View

Ma L, Feng F, Dong L, Zhang Z, Duan M, Liu L . Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics. 2018; 8(20):5690-5702. PMC: 6276293. DOI: 10.7150/thno.28742. View

Cucchetti A, Piscaglia F, Cescon M, Colecchia A, Ercolani G, Bolondi L . Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013; 59(2):300-7. DOI: 10.1016/j.jhep.2013.04.009. View

Liao S, Su T, Jeng Y, Liang P, Chen D, Chen C . Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma. Hepatology. 2018; 69(1):209-221. DOI: 10.1002/hep.30162. View

Torbenson M . Morphologic Subtypes of Hepatocellular Carcinoma. Gastroenterol Clin North Am. 2017; 46(2):365-391. DOI: 10.1016/j.gtc.2017.01.009. View

Koo H, Park M, Kim M, Lim J, Yu J, Jin H . Radiological and clinical features of sarcomatoid hepatocellular carcinoma in 11 cases. J Comput Assist Tomogr. 2008; 32(5):745-9. DOI: 10.1097/RCT.0b013e3181591ccd. View

10.

Shin E, Ryu H, Kim S, Jung H, Jang J, Lee K . The clinicopathological significance of heat shock protein 70 and glutamine synthetase expression in hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2011; 18(4):544-50. DOI: 10.1007/s00534-010-0367-0. View

11.

Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G . Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006; 44(4):723-31. DOI: 10.1016/j.jhep.2005.12.015. View

12.

Nishi H, Taguchi K, Asayama Y, Aishima S, Sugimachi K, Nawata H . Sarcomatous hepatocellular carcinoma: a special reference to ordinary hepatocellular carcinoma. J Gastroenterol Hepatol. 2003; 18(4):415-23. DOI: 10.1046/j.1440-1746.2003.02888.x. View

13.

Fu S, Qi C, Xiao W, Li S, Peng B, Liang L . Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery. 2013; 154(3):536-44. DOI: 10.1016/j.surg.2013.02.014. View

14.

Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C . Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology. 2016; 64(6):2038-2046. DOI: 10.1002/hep.28710. View

15.

Chun Y, Pawlik T, Vauthey J . 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol. 2017; 25(4):845-847. DOI: 10.1245/s10434-017-6025-x. View

16.

Gao Q, Wang X, Qiu S, Yamato I, Sho M, Nakajima Y . Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009; 15(3):971-9. DOI: 10.1158/1078-0432.CCR-08-1608. View

17.

Di Tommaso L, Destro A, Seok J, Balladore E, Terracciano L, Sangiovanni A . The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol. 2009; 50(4):746-54. DOI: 10.1016/j.jhep.2008.11.014. View

18.

Bouattour M, Raymond E, Qin S, Cheng A, Stammberger U, Locatelli G . Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2017; 67(3):1132-1149. PMC: 5873445. DOI: 10.1002/hep.29496. View

19.

Dal Bello B, Rosa L, Campanini N, Tinelli C, Torello Viera F, DAmbrosio G . Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res. 2010; 16(7):2157-66. DOI: 10.1158/1078-0432.CCR-09-1978. View

20.

Wang Q, Cui B, Weng J, Wu Q, Qiu J, Lin X . Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma and carcinosarcoma of the liver. J Gastrointest Surg. 2012; 16(9):1715-26. DOI: 10.1007/s11605-012-1946-y. View